News & Updates
10th FDA Approval for Abramson Cancer Center
Friday, June 12, 2020
The Abramson Cancer Center along with Philly Fights Cancer is pleased to announce that the Food and Drug Administration (FDA) has approved Cerianna (Fluroestradiol F18) for injection purposes. Fluroestradiol F18 is the first FDA-approved PET imaging agent used for patients with metastatic breast cancer. This will help with the detection of estrogen receptors (ER)-positive lesions in the imaging process instead of having to perform biopsies.
We are Penn Proud about this FDA approval which was made possible through many years of effort, and determination in academia and the National Cancer Institute (NCI). This new injection would not be possible without the groundbreaking contributions of Abramson Cancer Center members and Radiology faculty. Thank you, David Mankoff, MD, PhD, Erin Schubert, Angela DeMichele, MD, MSCE, Lewis Chodosh, MD, PhD, Amy Clark, MD, MSCE, Robert Mach, PhD, and Sharon Lee, PhD.
This is the 10th FDA approval for cancer based on studies led or co-led by members of the ACC since 2017.
Share this post
The Abramson Cancer Center along with Philly Fights Cancer is pleased to announce that the Food and Drug Administration (FDA) has approved Cerianna (Fluroestradiol F18) for injection purposes. Fluroestradiol F18 is the first FDA-approved PET imaging agent used for patients with metastatic breast cancer. This will help with the detection of estrogen receptors (ER)-positive lesions in the imaging process instead of having to perform biopsies.
We are Penn Proud about this FDA approval which was made possible through many years of effort, and determination in academia and the National Cancer Institute (NCI). This new injection would not be possible without the groundbreaking contributions of Abramson Cancer Center members and Radiology faculty. Thank you, David Mankoff, MD, PhD, Erin Schubert, Angela DeMichele, MD, MSCE, Lewis Chodosh, MD, PhD, Amy Clark, MD, MSCE, Robert Mach, PhD, and Sharon Lee, PhD.
This is the 10th FDA approval for cancer based on studies led or co-led by members of the ACC since 2017.